While Venn Life looks for a successor, Chief Executive Tony Richardson will take over Hartshorn's responsibilities.
Shares were down 1.7% on Wednesday at
Wed, 21st Mar 2018 11:03
While Venn Life looks for a successor, Chief Executive Tony Richardson will take over Hartshorn's responsibilities.
Shares were down 1.7% on Wednesday at
(ShareCast News) - Venn Life Sciences has signed a €1m contract with a leading French biotech company. The AIM listed clinical research organisation announced the deal on Friday. The two-phase project is centred on acute T-cell leukaemia, and will cover multiple regions including France, the UK and
Read more(ShareCast News) - Clinical trial services provider Venn Life Sciences posted a narrower interim pre-tax loss and has agreed to acquire Kinesis Pharma BV. In the six months to the end of June, the London-listed company saw its pre-tax loss narrow from €987,000 (£716,000) to €259,000, while revenue a
Read more(ShareCast News) - Venn Life sciences said it has had a strong first half, with revenues up 170% on the previous year. In a very brief trading update, the company, which provides clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, reported
Read more